CRDF · Cardiff Oncology, Inc.
$1.21
+0.04 (+3.42%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$95.30M
Shares
77.80M
Volume · Sep 30
564.68K
Avg daily vol (3M)
1.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.21
Open$1.17
Day$1.17–1.25
52W close$0.81–3.21
Avg vol 30d801K
Short int12.3M · 15.8% float · 12.1d
Short vol74%
Last earningsJun 3, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 28, 2026
Est · unconfirmed
· in 8 wks
filed Aug 11, 2026
call held Feb 27, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$508,000
Trailing 12 months
Net income (TTM)
−$40.05M
Trailing 12 months
Revenue growth YoY
-14.0%
Year over year
Operating margin
-8,320.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$34.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
-43.8%
Trailing year
Short interest
15.8%
Latest settlement · 12.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
+15%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
−28%
trailing
YTD return
−57%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +20 funds added
Insider flow
Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest
Rising
15.82% of float · ▲ +5.3% MoM · 12.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
+50%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-38.0M
Balance sheet
$10.8M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
+15%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +20 funds added
Insider flow
Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest
Rising
15.82% of float · ▲ +5.3% MoM · 12.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 17%
Range high $3
vs 200-day avg -26%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRDF
this stock
Cardiff Oncology, Inc.
|
$95.30M | -56.9% | +49.6% | — | 15.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRDF | -7.6% | +17.5% | -27.5% | +22.2% | -56.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -7.0% | +17.4% | -39.7% | +22.8% | -68.8% |